Clinical trial | Median age(range) | MSC frequency | MSC dosage | aGVHD morbidity (%) | cGVHD morbidity (%) | Survival rate (%) | Follow-up time | References |
---|---|---|---|---|---|---|---|---|
No.21 | Standard prophylaxis group:30y (18–60) Standard prophylaxis + MSCs group:37y (20–63) | 1 | 1 × 106/kg | 100d grade II–IV aGVHD:Standard prophylaxis group:29.4 Standard prophylaxis + MSCs group:9.4 p = 0.041 | N/A | exact time unknown:Standard prophylaxis group:61.8 Standard prophylaxis + MSCs group:81.2 p < 0.05 | N/A | Kuzmina et al. [42] |
No.21 | 34y (17–63) | 1 | 1.2 (0.9–1.65) × 106/kg | 100d grade II–IV aGVHD:Standard prophylaxis group:20.5 Standard prophylaxis + MSCs group:10.2 | N/A | N/A | N/A | Shipounova et al. [43] |
No.34 | MSC group:58y (21–69) historic group:55y (10–69) | 1 | N/A | 100d grade II–IV aGVHD:MSC group:35 historic group:56 grade IV aGVHD:MSC group:10 historic group:19 | 1y moderate/severe cGVHD:MSC group:65 | 1y:MSC group:80 historic group:44 p = 0.02 | 560d | Baron et al. [93] |
No.38 | MSC group:6.9y (3.3–12.5) historic group:9.5y (8.4–18.7) | 1 | 1/5 × 106/kg | grade I–II aGVHD:MSC group:57.1 historic group:62.5 p = 0.83 grade III–IV aGVHD:MSC group:14.3 historic group:0 p = 0.36 | extensive cGVHD:MSC group:14.3 historic group:50.0 p = 0.27 | 2y:MSC group:85.7 historic group:55.6 p = 0.15 | N/A | Lee et al. [94] |
No.60 | N/A | 3.7 (2–4) | 3 × 107/100 mL/m | N/A | 2y:MSC group:27.4 control group:49.0 p = 0.021 | 2y:MSC group:66.1 historic group:61.3 p > 0.05 | 51m | Gao et al. [92] |